ATOS (Atossa Therapeutics) Moat Score: 3/10 (As of Jun. 24, 2026)


ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $1.76
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Moat Score?

Atossa Therapeutics ATOS -7.89% 26 Moat Score is 3 as of Jun. 24, 2026. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,405 Biotechnology companies, Atossa Therapeutics ranks better than 75.52% on this metric.

Atossa Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Atossa Therapeutics has No Moat: Atossa Therapeutics Inc has some potential due to its R&D efforts, but lacks significant market leadership, brand strength, or regulatory barriers. The biotech industry is highly competitive, limiting its competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Atossa Therapeutics might have No Moat - Very weak/transient advantages.

Atossa Therapeutics  (NAS:ATOS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Atossa Therapeutics Moat Score Related Terms

ATOS vs LTRN, ESLA, NTRB: Moat Score Comparison

For the Biotechnology subindustry, Atossa Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Moat Score falls into.


ATOS
26GF Score
Atossa Therapeutics Inc ATOS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Atossa Therapeutics (ATOS) has a Moat Score of 3 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Atossa Therapeutics ranks #344 out of 1405 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Atossa Therapeutics' Moat Score too high?
Atossa Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Atossa Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Atossa Therapeutics ranks #344 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' Moat Score compare to LTRN and ESLA?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #344 out of 1405 companies for Moat Score. This places Atossa Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Atossa Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atossa Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atossa Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current Moat Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price